In The UK Why Do We Have 140 licensed Dermal Fillers Whereas there are only 25 in the USA ?

140 Fillers or 25? What the Difference Between CE Marking and FDA Approval Actually Means for Patients and Practitioners

market has over 140 CE-marked dermal fillers. The United States has fewer than 25 FDA-approved . That disparity is not a coincidence — and understanding why it exists has genuine clinical implications.

Over 140 dermal fillers are currently licensed and CE-marked for use in the market. The United States, by contrast, has fewer than 25 by the FDA. The same fundamental product category, hyaluronic acid or calcium hydroxylapatite for facial enhancement, to dramatically different degrees of rigour in two of the world’s most regulatory .

The disparity is not a reflection of greater or a more range of genuinely distinct clinical products. It is a reflection of fundamentally different philosophies, and understanding those is one of the most things a in the UK aesthetic market can do.

The CE mark ( Européenne) is a that a with European Union safety, health, and environmental requirements. For medical devices, dermal fillers, CE under the EU Device Regulation (MDR 2017/745) means that the product has been assessed for safety and performance, that the meets MDR standards, and that the is registered in the Database on Devices (EUDAMED) with a Unique Device Identifier.

What CE marking does not require, or has not historically required in the way that FDA approval does, is a comprehensive demonstration of clinical efficacy independently reviewed, prospectively conducted clinical trials. The assessment process has traditionally been conducted by «notified bodies» rather than by a government agency with the power and of the FDA, and the bar for that a product as intended has been lower than the bar for FDA approval.

It is worth acknowledging that the European regulatory has in recent years. The new MDR 2017/745, which replaced the Device Directive, has introduced more stringent requirements for evidence, post-market surveillance, and . Dermal fillers are now classified under Annex XVI as without an intended medical but with significant safety implications, subject to Common Specifications that require clinical evaluation data. The of travel is towards rigour. The legacy of the old regime, a large number of products that the market under a less demanding framework, persists in the number of CE-marked currently .

The FDA classifies most dermal as Class III — the highest risk classification, shared with and defibrillators. This classification the most approval pathway: Pre-Market (PMA), which requires the to submit clinical trial data both the safety and the of the for each specific use. Clinical trials intended to support the approval of a dermal filler product are and by the FDA prior to study through the Investigational Device Exemption . The FDA dermal fillers for specific, defined locations and for one area does not automatically extend to another.

The FDA’s for approval is worth particular . A product for folds requires separate clinical trial evidence before it can be for lip augmentation. A for the face requires separate before it can be used on the hands. This granular, indication-level requirement has no direct in the CE marking process, and it means that the an FDA-approved is both more extensive and more specifically applicable to the in which it is used.

The in the number of available is not primarily a of the diversity of clinical need. Hyaluronic OnabotulinumtoxinAAbobotulinumtoxinAIncobotulinumtoxinAPrabotulinumtoxinALetibotulinumtoxinARimabotulinumtoxinBHyaluronic Acid FillersCalcium Hydroxylapatite FillersPoly-L-lactic Acid FillersPolymethylmethacrylate FillersAutologous Fat GraftingForehead Lines TreatmentGlabellar Frown Lines TreatmentCrow’s Feet TreatmentBunny Lines TreatmentChemical Brow LiftLip FlipGummy Smile CorrectionMasseter ReductionJaw SlimmingDimpled Chin SmoothingCobblestone Chin SmoothingNefertiti Neck LiftMicro-BotoxMesotoxHyperhidrosis TreatmentChronic Migraine ReliefBruxism TreatmentTMJ TreatmentCervical Dystonia TreatmentNeck Spasm TreatmentBlepharospasm TreatmentLip AugmentationLip ContouringCheekbone EnhancementTear Trough FillersNasolabial Fold SofteningMarionette Line FillersLiquid RhinoplastyNon-Surgical Nose JobJawline ContouringJawline DefinitionChin AugmentationTemple VolumisingHand RejuvenationAcne Scar Subcision Filling fillers, across their many variations, share the same fundamental mechanism of action. The meaningful distinctions between products, molecular weight, degree of crosslinking, concentration, rheological properties, represent a relatively small number of types. The 140 products in Europe include a great many on established formulations that have entered the market with limited their performance from existing products.

This is not a trivial observation. A practitioner between products in the European market cannot assume that CE marking confers with FDA approval. The evidential basis for varies enormously, from products with extensive, conducted clinical trial data, to products whose CE rests primarily on demonstration of compliance and biocompatibility testing.

The practitioner who assumes that any filler is as thoroughly evaluated as an one is making an that the regulatory do not .

The of this regulatory disparity is that the burden of product evaluation falls more on the practitioner in the European market than in the one.

An between FDA-approved can be that each product has cleared a bar. A choosing between CE-marked is in a market where that confidence is not uniformly and where the responsibility to evaluate the behind individual products, rather than simply approval as a proxy for validation, is greater.

This connects directly to the problem we examined in an earlier piece in this series. The same critical reading skills that credible clinical from material apply with particular force to the evaluation of filler products, examining who funded the studies, what the study were, whether the evidence is indication-specific, and whether independent replication exists.

A filler that is CE-marked and to GMP standards by a may still have a clinical evidence base than its regulatory status implies.

The FDA’s granular, indication-level to has a safety dimension that is directly relevant to the vascular occlusion risks we have discussed elsewhere in this blog. The FDA has incorporated additional into its regulatory strategy for fillers used around the eyes, nose, and glabella — high-risk anatomical areas — requiring trials to and deliberately monitor for visual impairment and to have in place to quickly treat subjects if vascular occurs. This level of safety scrutiny is not a of CE marking for the same products.

The FDA’s adverse event reporting database for dermal fillers, the MDR database, is also a valuable that has no direct equivalent of scope and accessibility.

FDA adverse event for dermal fillers have steadily increased, with 1,478 in 2023, with system impairment continuing to be a common serious adverse event. The systematic collection and of this data allows practitioners, researchers, and to the safety of products in a way that is harder to achieve in the regulatory environment.

It would be misleading to suggest that the regulatory framework is static or indifferent to these concerns. The new MDR, fully from 2021, represents a tightening of requirements, and the Annex XVI Common Specifications for aesthetic introduced clinical obligations that did not exist under the old . The for post-market clinical follow-up and the obligation to in EUDAMED represent genuine in and .

The question is not whether Europe is moving in the right direction; it is. The question is whether the legacy of a less framework, and the 140-plus products that entered the market under it, is being addressed with sufficient rigour and speed.

The answer, for the trying to make evidence-based choices today, is that the regulatory label alone is an guide and that the habit of reading the small print, examining the evidence, and asking who funded the studies, is as necessary when choosing a filler as it is when any other clinical intervention.

The between 140 CE-marked and 25 ones is a in regulatory philosophy; in how much clinical is required before a product reaches the market, and how specifically that evidence must be tied to the indications for which the product will be used. That difference has practical for practitioners, for patients, and for the honest of evidence in .

A CE mark is a meaningful regulatory . It is not the same as FDA approval. the and applying the clinical that is part of what it means to practise aesthetic medicine in the market.

The views expressed in Clinical Perspectives are the own and reflect their and in aesthetic .

References

EU MDR 2017/745 Annex XVI and Common (EU) 2022/2346 for aesthetic injectables.  Commission.

FDA Summary: General Issues Panel Meeting on Dermal . U.S. Food and Drug Administration.2021. 

FDA Summary: General Issues Panel Meeting on Dermal . U.S. Food and Drug Administration.2024. 

Map for Injectable Dermal Fillers: US, EU, China, South Korea, Brazil. . 2026. 

CE Marked vs FDA Aesthetic Products. . 2025. https://e-fillers.com/blog/ce-marked-vs-fda-approved-aesthetic-products

What a Toxin Scientist Taught Us About Botulinum Toxin

How Can Anti-wrinkle Injections Be The Safest Treatment in Aesthetic Medicine — And Yet Paradoxically the Most Dangerous ?

6 Esher Park Avenue
Esher, Surrey KT10 9NP

Tel: ‬
Tel: ‭ ‬

© 2026
The Cosmetic Ltd
no.